CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  Breast cancer is one of the most rapidly evolving fields in oncology nursing and remains a challenge for many healthcare professionals. Furthermore, recent clinical research gains have made an abundance of treatment options available to patients with breast cancer, and published results from ongoing clinical trials continually lead to the emergence of new therapeutic regimens and changes in the use of existing treatments. To provide oncology nurses with the knowledge, information and strategies they can use to address the disparate needs of patients, this issue of the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with breast cancer. Upon completion of this CNE activity, oncology nurses should be able to better counsel and educate patients while developing up-to-date approaches for the management of this disease.
  
  PURPOSE STATEMENT
  To present the most current research developments in breast cancer and to provide the perspectives of a clinical investigator and nurse practitioner on the diagnosis and treatment of this disease.
  
  LEARNING OBJECTIVES

  • Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
  • Develop a plan to manage the side effects associated with systemic therapies to support quality of life and continuation of treatment.
  • Recall the recent FDA approval of neoadjuvant pertuzumab, and consider this therapeutic approach when evaluating appropriate patients with HER2-positive early breast cancer.
  • Develop an evidence-based algorithm for the initial and long-term treatment of localized and advanced estrogen receptor-positive breast cancer.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.

  ACCREDITATION STATEMENT
  
  CNE credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CNE credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  This is a video CNE program.
  
  CNE credit is no longer available for this issue
  
  ONCC/ILNA Certification
  The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.researchtopractice.com/ONUBreast115/ILNA
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — Ms Olson and Dr Yardley have no real or apparent conflicts of interest to disclose.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Genentech BioOncology and Novartis Pharmaceuticals Corporation.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: July 2015
  Expiration date: July 2016
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.